Last reviewed · How we verify

Sevoflurane or Propofol — Competitive Intelligence Brief

Sevoflurane or Propofol (Sevoflurane or Propofol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: General anesthetic. Area: Anesthesiology.

marketed General anesthetic GABA-A receptor, NMDA glutamate receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Sevoflurane or Propofol (Sevoflurane or Propofol) — University Health Network, Toronto. Sevoflurane and Propofol are general anesthetics that enhance inhibitory GABAergic neurotransmission and suppress excitatory glutamatergic signaling in the central nervous system to produce unconsciousness.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sevoflurane or Propofol TARGET Sevoflurane or Propofol University Health Network, Toronto marketed General anesthetic GABA-A receptor, NMDA glutamate receptor
Sevoflurane inhalant product Sevoflurane inhalant product Sunnybrook Health Sciences Centre marketed Volatile inhalational anesthetic GABA-A receptor, NMDA glutamate receptor
Sevorane (sevoflurane, Abbott) Sevorane (sevoflurane, Abbott) Medical University of Gdansk marketed Volatile anesthetic GABA-A receptor, NMDA glutamate receptor
General sevoflurane anaesthesia General sevoflurane anaesthesia KK Women's and Children's Hospital phase 3 Volatile anesthetic agent GABA-A receptor, NMDA glutamate receptor
Inhaled sedation with sevoflurane Inhaled sedation with sevoflurane University Hospital, Clermont-Ferrand phase 3 Volatile anesthetic GABA-A receptor, NMDA glutamate receptor
SEVOFLURANE SEVOFLURANE marketed General Anesthetic [EPC] 1995-01-01
Suprane DESFLURANE Baxter marketed General Anesthetic [EPC] GABA-A receptor; anion channel 1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (General anesthetic class)

  1. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  2. Chung-Ang University Gwangmyeong Hospital · 1 drug in this class
  3. Fresenius Kabi · 1 drug in this class
  4. Gangnam Severance Hospital · 1 drug in this class
  5. Rigshospitalet, Denmark · 1 drug in this class
  6. Seoul National University Hospital · 1 drug in this class
  7. Universidade Estadual Paulista Júlio de Mesquita Filho · 1 drug in this class
  8. University Health Network, Toronto · 1 drug in this class
  9. Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sevoflurane or Propofol — Competitive Intelligence Brief. https://druglandscape.com/ci/sevoflurane-or-propofol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: